Why Attend
The average consumer spends $5 a day on skincare, whilst using up to 515 synthetic chemicals daily to eradicate dermalogical concerns - how can this be good for skin? Introducing the Skin Microbiome Congress.
Following the mainstream focus on the gut microbiome and its role in health and disease, researchers and industry experts are now turning their attention towards the emerging relationship between the skin microbiome and healthy skin. This has the potential to revolutionise the beauty and personal care industry.
View highlights from the inaugural Skin Microbiome Congress, May 30-31, 2018
Join 200+ industry experts from multinational pharmaceutical, beauty and personal care companies, along with the independent skincare brands and innovative biotechs who are advancing the field.
Discover the potential of prebiotic, probiotic and postbiotic products being developed to protect and promote a healthy microbiome and ultimately combat dermatological conditions from acne and eczema to dandruff and skin allergies. Take advantage of:
- Effective Networking - Pre-schedule private meetings with any individual or company onsite using the online meeting scheduler application
- Cutting Edge Research – Discover the latest advancement in therapeutic & cosmetic products containing live bacteria, bacterial extracts, or active ingredients to promote & protect the skins microbiome
- Consumer Trends - Understand how consumers trends towards natural, organic products and active beauty are shaping the evolution of products adapted to the skin microbiome
- Clinical Trials – Explore how to design an effective clinical trial & translate research into clinically & commercially viable therapeutics
- Competitive Edge – Determine how to differentiate your product line & seize this market opportunity, gaining market share with scientifically backed products
- Regulation – Understand the different paths to market & regulatory considerations necessary to launch a cosmetic or therapeutic product
With an increasing consumer trend towards natural products, what’s more natural than harnessing the bacteria on your skin? Don't miss your chance to understand the next generation of natural skincare products!
Sample of Industry Leaders & Innovators attending our Boston Summit
The Agenda
Simply fill in this form and we'll send you a PDF version of the agenda immediately. We need some information to know where to send the file and how to address our email to you.
We've received great feedback on other similar events...
3rd Annual European Microbiome Congress: The Next Big Thing in Microbiome...Skin
Beauty & Money Summit 2018
Download Agenda
Skincare Spotlight Selection Committee
Joy Chen
Travis Whitfill
Travis Whitfill is an Associate Research Scientist in the Department of Pediatrics. His background began in molecular biology and biochemistry, after receiving scientific training at the MD Anderson Cancer Center and Duke University. He is the co-founder of several additional startup companies, including a Connecticut-based microbiome company, Azitra Inc. He brings strong background in entrepreneurship and business, and is also a partner in a venture capital fund, Bios Partners, bringing experience in public markets, drug development, and venture capital investments.
His research interests are in pediatric emergency medicine and health policy and to improve pediatric acute care across the United States.
David H. Crean
David H. Crean, Ph.D is a Managing Director at Objective Capital Partners where he leads the firms life science investment banking transactions. Dr. Crean has in excess of 20 years of life sciences R&D and corporate development transactional experience in the pharmaceutical industry where he was responsible for leading mergers, acquisitions, licensing and collaborations, and establishing corporate strategy. Davids transaction experience in the life sciences sector includes sell-side, buy-side, licensing and capital raising activities. He has supported company and client engagements in both U.S. domestic and foreign transactions including Japan, China and Europe.
Prior to joining Objective Capital Partners, Dr. Crean served over 20 years in specialty pharmaceuticals; namely at Allergan (NYSE:AGN) and Aqua Pharmaceuticals, a private equity-backed company, prior to being sold to Almirall, SA. (BME:ALM). Dr. Crean has led transaction execution in a wide range of specialty areas including aesthetic and therapeutic dermatology, OTC skin care, neurological disorders / CNS, pain, inflammation, ophthalmology, oncology and diagnostics/ detection. His corporate pharmaceutical experience spans research and development expertise in small molecules, biologics, prescription drugs, OTC products and medical devices.
Dr. Creans pharmaceutical and biotechnology leadership experience includes serving in key leadership roles in the development and/or growth of many commercial portfolios including: BOTOX, LUMIGAN, JUVEDERM, LATISSE, ACZONE, TAZORAC, MONODOX, FLUOROPLEX, XOLEGEL and VERDESO. Concurrent with Objective Capital, Dr. Crean serves as a strategic business advisor for several life science companies, is an active member on BIOCOMs Capital Development Committee and BIO International 2017 Partnering Committee and a contributing member on the Membership & Program Committees for the Association for Corporate Growth (ACG) in San Diego.
Dr. Crean holds a Masters of Business Administration Degree with a finance concentration from Pepperdine University School of Management. Additionally, he holds a Doctorate of Philosophy Degree in Biophysics and a Masters of Science Degree in Oncology from the State University of New York at Buffalo. Dr. Crean also earned a Bachelor of Science Degree in Biology from Canisius College.
Dr. Crean holds FINRA Series 79 and Series 63 licenses and is a Registered Representative of BA Securities LLC, Member FINRA SIPC.
Raymond Ip
Imke Meyer
Julia French
Dr Phil Bolton
Phil obtained his Ph.D in organometallic chemistry from the University of Durham in 2000 and subsequently joined P&G where he worked on new technology development for the hair colourant category. Phil then joined RB in 2006 and has worked across a number of Innovation and Category R&D ROLES IN THE UK, Italy, Singapore and the US, becoming a director in 2010 and returning back to the UK based RB HQ in April 2015.
Phil currently leads the Outside Innovation team and has responsibility for delivering new and innovative solutions to the Health category pipelines. This can be anything from an ingredient in the product, through to products themselves, forging sustainable partnerships as well as being a strategic innovation partner for the senior category leadership within RB.
John Gannon, Ph.D.
Currently, John serves as the Microbiome Platform Technical Team Leader within DuPont’s Industrial Biosciences. He designed, initiated, and developed the technical infrastructure that serves as the research platform for Microbiome related initiatives and leads the Microbiome technical team for the DuPont Industrial Biosciences business. He has 27 years of experience with DuPont and has served as the lead scientist and/or technical leader for a variety of microbiology, microbial ecology, and environmental fate-related initiatives.
He was recruited by DuPont in 1991 to start up DuPont’s environmental fate competency for industrial chemicals. He became globally-recognized as a leading industrial expert in environmental sciences, which is based on his unique combination of expertises in biodegradation, microbial ecology, microbial physiology, environmental chemistry, and computational sciences. He has served on Science Advisory Boards, advisory groups, and expert panels for Environment Canada, U.S. EPA, Trent University, Rutgers Environmental & Occupational Safety & Health Institute, and currently with the NJ Department of Environmental Protection. Over the last 5 years, he has focused his work on microbiology related initiatives focused on further development of DuPont’s Microbiome Platform.
He received his Ph.D. in Microbiology from New York University and his Postdoc was in the laboratory of Dr. Martin Alexander at Cornell University.
Marie Cesbron
Marie Cesbron is a health&beauty leader with over two decades of hands-on experience transforming global brands such as Lancôme, Maybelline, Vichy Laboratories and building innovation capabilities within L’Oréal R&D as well as Walgreens Boots Alliance. She currently is Director of Innovation at Walgreens Boots Alliance’s consumer brand arm. Deeply in tune with changing consumer behaviours and macro-trends, she is passionate about the merge between wellness, health and beauty. She has worked and lived in Paris, New York and London. Marie holds an MS in Marketing from HEC Paris and a BS in Psychology from Paris Descartes University.
The Speakers
Jasmina Aganovic
Jasmina Aganovic is the President of Mother Dirt, a line of biome-friendly personal care products focused on restoring and maintaining the balance of the skin biome. The technology is based off research from AOBiome Therapeutics, a biotech company focused on transforming human health through products that restore Ammonia-Oxidizing Bacteria (AOB), which current hygiene practices have stripped from the modern microbiome. She is a cosmetics and consumer goods entrepreneur who received her degree in chemical and biological engineering from MIT. Her career path combined her technical background with roles at consumer brands like LVMH, Fresh, and Living Proof.
Dana Hosseini
A serial entrepreneur who has managed and co-founded a number of genomics-based companies including, ProdermIQ, Iceland Genomics and DiThera. Mr. Hosseini's skills in international medical device/diagnostic sales and marketing were developed at Abbott Laboratories, Ortho Clinical Diagnostics (Johnson & Johnson) and Sequenom, where he held executive and management positions in business development, and sales and marketing functions. He has 25+ years of extensive experience working with global biotech, pharmaceutical companies and healthcare providers. He received both his B.Sc. and MBA from the University of British Columbia.
Hasti Nazem
Hasti is part of the founding team of Kindra, leading product development and education. Kindra is developing innovative estrogen-free solutions targeting the top pain points of the 34+ symptoms of menopause. With nearly 10 years of experience at the intersection of life sciences, health and wellness, and consumer brand building, Hasti integrates targeted product formulation development with cutting edge technical advancements. Her deep scientific communications experience helps to empower consumers to better understand their health, and bridge gaps often overlooked in women's health. Hasti's work has been featured in has been featured in The New York Times, Forbes.com, (O) Oprah Magazine, Harper's Bazaar, Women's Health Magazine, and in healthcare public affairs and pharmaceutical trade association publications.
Allison Krebs Bensch
Allison Krebs-Bensch, a graduate of Vanderbilt University, has been intrinsically involved in her family’s pharmaceutical business, US Pharmaceutical Corporation, since graduating. Rolling up her sleeves, Allison dove into learning every aspect of the business from Sales to R & D, before eventually taking over the responsibilities of CEO.
Allison’s accomplishments include being listed as an inventor on patents for Improved Toleration of Iron Supplement Compositions. Additionally, she has developed, progressive & pending, patented formulations utilizing new probiotic strains for various applications of use. Most recently, she has co-founded and is CEO of a start-up probiotic skin care company, BeBe and Bella. This company specializes in delivering probiotics and their fermented filtrates, both orally and topically, for improved natural beauty. As co-founder, Allison has been invited to be a Speaker at several symposiums related to the science behind probiotics.
Emma Taylor
Dr. Emma Taylor the CEO and co-founder of Naked Biome, a microbiome therapeutics company, focused in acne She is a UCLA-trained and board certified Dermatologist and Dermatopathologist, and former assistant professor of Dermatology and Dermatopathology at UCLA, where she c0-founded Naked Biome. She is also an inventor of 2 published patents, has published in notable journals such as Nature and the Journal of the American Academy of Dermatology, and is the author on more than 40 book chapters.
Richard Andrews
Mr. Andrews has spent most of his career as a C level executive leading operations, finance, and commercial and clinical development for biotechnology firms focused on new products that address inflammatory disease. Mr. Andrews has been instrumental in translating research and academic discoveries into product development and advanced clinical programs, building alliances and partnerships and organizing operational teams. Financing processes led by Mr. Andrews have secured over $130M in equity funding for new ventures. His work has been primarily focused on skin disease, pneumonia, infant hypoxic ischemia and kidney failure. Early in his career, Mr. Andrews led the commercialization of several natural cell systems to prevent disease on fruits and vegetables and launched several DNA diagnostic tests for periodontal disease. Mr. Andrews received graduate degrees in physical biochemistry (MS), and technology management (SM) from Purdue University, and the Massachusetts Institute of Technology, respectively. He also has an undergraduate degree in Chemistry (BS) from Hobart College.
Defne Saral
Currently Defne is the business leader for the commercial and technology offering of DuPont Industrial Biosciences (IB) to the personal care and cosmetics industry. She is part of the commercial industry leadership team, has responsibility for profit & loss and leads the global personal care team. She has 22 years of experience in global companies across a variety of industries.
Defne joined DuPont in 2005 after her MBA and has held commercial roles in marketing, sales, product management and business development. She has worked in specialty materials and ingredients for the fire fighting industry, textiles, paints & coatings, automotive, construction and retail. Prior to personal care, she was leading the food enzymes unit of IB developing offerings to improve freshness, optimize production, add texture, ensure quality consistency and reduce waste, water and energy consumption.
Prior to DuPont, she worked for 7 years at Philip Morris International, starting in Operations for Eastern Europe integrating acquisitions, moving to M&A, was Marlboro brand manager for Switzerland and head of strategic planning for the worldwide duty free unit.
Defne holds an MBA from IMD, Switzerland and a Bachelor in Systems Science Engineering from the University of Pennsylvania, USA. She was born in the US, is of Turkish origin, and is a Swiss citizen.
David Tyrrell
David’s experience in skincare has spanned over 15 years. During his tenure at Kimberly-Clark he held positions in Corporate Research, New Product Development and Technology Scouting & Alliance Management. He has been active in identifying a variety of consumer and medical device technologies and products for in-licensing and led international research efforts in the biological characterization of naturally sourced skincare ingredients. David has a BS in Chemistry and a PhD in Biochemistry.
Qun Wang
Ronie Schmelz
Travis Whitfill
Travis Whitfill is an Associate Research Scientist in the Department of Pediatrics. His background began in molecular biology and biochemistry, after receiving scientific training at the MD Anderson Cancer Center and Duke University. He is the co-founder of several additional startup companies, including a Connecticut-based microbiome company, Azitra Inc. He brings strong background in entrepreneurship and business, and is also a partner in a venture capital fund, Bios Partners, bringing experience in public markets, drug development, and venture capital investments.
His research interests are in pediatric emergency medicine and health policy and to improve pediatric acute care across the United States.
Julia French
Joy Chen
Stephen Roman
Elsa Jungman
Dr Phil Bolton
Phil obtained his Ph.D in organometallic chemistry from the University of Durham in 2000 and subsequently joined P&G where he worked on new technology development for the hair colourant category. Phil then joined RB in 2006 and has worked across a number of Innovation and Category R&D ROLES IN THE UK, Italy, Singapore and the US, becoming a director in 2010 and returning back to the UK based RB HQ in April 2015.
Phil currently leads the Outside Innovation team and has responsibility for delivering new and innovative solutions to the Health category pipelines. This can be anything from an ingredient in the product, through to products themselves, forging sustainable partnerships as well as being a strategic innovation partner for the senior category leadership within RB.
Imke Meyer
Raymond Ip
Eric Huang, PhD
Kit Wallen-Russell
With a Masters Degree in Geophysics from University College London (UCL), twice published scientific author, and JooMo Co-Founder Kit published a peer-reviewed paper in 2017 that describes the first ever mechanism to determine whether skin is healthy or not. As director of the Pavane Research Centre (the R&D arm behind all ground-breaking JooMo technology), he discovered that the ONLY indicator of healthy skin was high microbial biodiversity, not the presence/lack of particular microbes. The immense power of his discovery meant that, for the first time, it was possible to determine whether everyday cosmetics really are the primary cause of the skin allergy epidemic that’s raging across the western world. To do so, Kit formed a partnership with top European institution, The Medical University of Graz, to test everyday cosmetics, including JooMo, for their effect on skin health. The extremely intriguing results from the seminal study will have been published by Kit at the time of the event. Both Kit and Nick aim to dispel the myths and ill-education surrounding Probiotics within the industry, and distance JooMo from the Pro-/Pre- Biotics label. JooMo is NOT a probiotic.
John Gannon, Ph.D.
Currently, John serves as the Microbiome Platform Technical Team Leader within DuPont’s Industrial Biosciences. He designed, initiated, and developed the technical infrastructure that serves as the research platform for Microbiome related initiatives and leads the Microbiome technical team for the DuPont Industrial Biosciences business. He has 27 years of experience with DuPont and has served as the lead scientist and/or technical leader for a variety of microbiology, microbial ecology, and environmental fate-related initiatives.
He was recruited by DuPont in 1991 to start up DuPont’s environmental fate competency for industrial chemicals. He became globally-recognized as a leading industrial expert in environmental sciences, which is based on his unique combination of expertises in biodegradation, microbial ecology, microbial physiology, environmental chemistry, and computational sciences. He has served on Science Advisory Boards, advisory groups, and expert panels for Environment Canada, U.S. EPA, Trent University, Rutgers Environmental & Occupational Safety & Health Institute, and currently with the NJ Department of Environmental Protection. Over the last 5 years, he has focused his work on microbiology related initiatives focused on further development of DuPont’s Microbiome Platform.
He received his Ph.D. in Microbiology from New York University and his Postdoc was in the laboratory of Dr. Martin Alexander at Cornell University.
Richard LaDuca
Currently Rich is part of the technology leadership team within DuPont’s Industrial Biosciences (IB) Business. He works within a portfolio management team and has direct responsibilities for resource allocation for projects within IB as well as with our cross pillar partner programs. He has 34 years of experience in the development of bio-based products and new business initiatives.
Rich started his career in industrial biotechnology in 1984 as a research scientist when he joined Kodak’s Research Labs working with an interdisciplinary team to develop microbial cell factories to produce biochemicals. He has worked on programs to produce lysine, threonine, biotin, tryptophan, indigo and ascorbic acid. He was part of the Kodak team that helped form Genencor International where his efforts transitioned from research to business development. He has had an active role in establishing partnering relationships in the biochemicals and biomaterials science areas with companies such as Archer Daniels Midland (ADM), Eastman Chemical Co. (Ascorbic Acid) , Dow Corning (Silicon Biotechnology Platform) and The Goodyear Tire & Rubber Company (BioIsoprene).
Rich holds a Ph.D. in Microbial Cell Physiology from The University of Buffalo (Roswell Park Mem. Inst.) and completed a Post doctoral Fellowship Program in Biochemistry at the University of Rochester.
Suneer Jain
I am a driven, educated, and enthusiastic scientist that believes in the healing of molecular medicine. Over the past several years, my career has afforded me the opportunity to work with some of the nation’s most foremost experts in the fields of molecular medicine, sequencing, and cell technology. I have worked on a number of exciting and innovative projects and was part of the team that established the Illumina Clinical Services Laboratory and worked to successfully sequence the first whole human genome in a CLIA-certified, CAP-accredited laboratory.
Céline Blanchard
After finalizing her study of biology, Céline received her M.Sc. in Cosmetic Natural Active Ingredients from ISIPCA in Versailles, France.
She held positions in New Product Development, Scientific Communication and Innovation Management at several raw materials’ suppliers and currently, Céline is part of the R&D department within BIOEUROPE as Cutaneous Biology Research Engineer.
Michael Hoptroff
Michael Hoptroff, has over 20 years’ experience working on the microbiology of Beauty and personal Care. His research has spanned the development and formulation of topical antimicrobials to the characterisation and modulation of the microbiomes of skin, scalp and the oral mucosa. Having recently returned from four years secondment in China Michael is currently leading the Unilever UK Personal Care microbiology team.
Greg McParland
Wayne Willis
Sponsors
Associate Partners
Event Partner
Media Partners
Who Will Be There
-
Kisaco Audience Breakdown ChartMultinational Beauty & Personal Care Companies15%
-
Kisaco Audience Breakdown ChartMultinational Pharmaceutical Companies15%
-
Kisaco Audience Breakdown ChartSkincare Brands & Biotechnology Companies60%
-
Kisaco Audience Breakdown ChartFormulators, Ingredients Suppliers & Packaging Manufacturers5%
-
Kisaco Audience Breakdown ChartSequencing Companies & Solution Providers5%
-
Multinational Beauty & Personal Care Companies15%
-
Multinational Pharmaceutical Companies15%
-
Skincare Brands & Biotechnology Companies60%
-
Formulators, Ingredients Suppliers & Packaging Manufacturers5%
-
Sequencing Companies & Solution Providers5%
Venue
Hotel Kabuki, 625 Post St, San Francisco, CA 94115, USA
The 2nd Skin Microbiome Congress wil be taking place in Hotel Kabuki, Japantown, San Francisco.
Hotel Kabuki is one of the few boutique hotels just steps from Pacific Heights’ famed Fillmore District, and provides easy access to some of San Francisco’s most exciting dining, shops, and sights, including Union Square, the Golden Gate Bridge, and Lombard Street.
Bedroom rate: $319 per night + Tax
Book now:
W: Book online
T: 415-614-5423
We have only 20 rooms available at this special rate, please quote KISACO RESEARCH to secure yours.
Conference Packages
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
PARTNER WITH US
Based on your objectives, we can create bespoke packages designed specifically for you. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding, and Networking.
Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact [email protected]
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.
